Merck Beats Estimates as Keytruda Demand Lifts Earnings Outlook

businesscompany-earnings 5 posts · 5 accounts

Merck & Co. reported first-quarter revenue of $16.29 billion, beating analysts' estimates of $15.89 billion, as demand for its flagship Keytruda cancer drug and newer products supported sales. The company posted a per-share loss of $1.28, narrower than the expected $1.48 loss.

For 2026, Merck forecast revenue of $65.8 billion to $67.0 billion and per-share earnings of $5.04 to $5.16, compared with consensus estimates of about $66.5 billion in revenue and $5.11 a share. The outlook reflects a narrower range, while the company also raised its full-year earnings guidance.

From the sources (5 posts)

@business

Merck & Co. reports first-quarter sales that beat Wall Street estimates as demand ramps up for newer products

@cnbc

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

@wallstengine

$MRK | Merck Q1 Earnings Highlights 🔹 Revenue: $16.29B (Est. $15.89B) 🟢 🔹 EPS: ($1.28) (Est. ($1.48)) 🟢 FY26 Guide: 🔹 Revenue: $65.8B-$67.0B (Est. $66.493B) 🟡 🔹 EPS: $5.04-$5.16 (Est. $5.11) 🟡

@firstsquawk

MERCK & CO Q1 2026 EARNINGS - SALES $16.29B (EST $15.83B) - ADJ LOSS/SHR $1.28 (EST LOSS $1.51) - KEYTRUDA REV. $8.03B, +12% Y/Y - GARDASIL REV. $1.07B (EST $1.04B) - ANIMAL HEALTH SALES $1.79B (EST $1.68B) - INCL CHARGE OF $3.62 PER SHARE

@wsj

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow.

Stellantis Drops 7% Despite First-Quarter Earnings Beat Starbucks Raises Outlook After Sales and Earnings Top Estimates